Moderna 8-K Signals Upcoming Financial Disclosure

Ticker: MRNA · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: regulation-fd, financial-update, corporate-event

TL;DR

**Moderna just filed an 8-K, expect new financial results soon!**

AI Summary

Moderna, Inc. filed an 8-K on January 8, 2024, to report an event related to its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that Moderna is providing an update on its financial performance, likely in preparation for an upcoming investor presentation or earnings call. For investors, this matters because it signals that new financial information about Moderna's operations will be disclosed, which could impact the stock's valuation and future outlook.

Why It Matters

This filing indicates Moderna is about to release new financial information, which could significantly influence investor perception and stock price.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing indicating upcoming financial disclosures, not a disclosure of negative events itself.

Analyst Insight

A smart investor would monitor Moderna's news channels closely for the actual financial disclosure that this 8-K foreshadows, as that will contain the actionable information.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the purpose of this 8-K filing by Moderna, Inc.?

This 8-K filing by Moderna, Inc. is to report an event related to 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure', indicating that the company is providing an update on its financial performance as of January 8, 2024.

What specific items are mentioned in the 'ITEM INFORMATION' section of the filing?

The 'ITEM INFORMATION' section specifically mentions 'Results of Operations and Financial Condition', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024, which is also the date of the report.

What is Moderna, Inc.'s trading symbol and on which exchange is its common stock registered?

Moderna, Inc.'s common stock trades under the symbol MRNA and is registered on The Nasdaq Stock Market LLC.

What is the business address and phone number of Moderna, Inc. as stated in the filing?

Moderna, Inc.'s business address is 200 Technology Square, Cambridge, MA 02139, and its telephone number is (617) 714-6500.

From the Filing

0001682852-24-000004.txt : 20240108 0001682852-24-000004.hdr.sgml : 20240108 20240108070343 ACCESSION NUMBER: 0001682852-24-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 24518287 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 8-K 1 mrna-20240108.htm 8-K mrna-20240108 0001682852 false 0001682852 2024-01-08 2024-01-08   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 MODERNA, INC. (Exact name of registrant as specified in its charter) Delaware   001-38753   81-3467528  (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.)   200 Technology Square Cambridge , MA   02139 (Address of principal executive offices)   (Zip code) Registrant’s telephone number, including area code: ( 617 )  714-6500 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share MRNA The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company       ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐ Item 2.02 Results of Operations and Financial Condition. On January 8, 2024 , Moderna, Inc. (the “Company”) issued a press release (the “Press Release”) in connection with the Company’s presentation on the same date at the 42nd Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2023. Specifically, the Press Release states that (i) the Company generated approximately $6.7 billion in product sales (unaudited) for the fiscal year ended December 31, 2023 from sales of its COVID-19 vac

View on Read The Filing